The authors review current evidence from randomized trials and meta-analyses regarding the effectiveness of several categories of drugs in the treatment of patients with AMI, including beta-adrenergic antagonists, angiotnesin-converting-enzyme (ACE) inhibitors, nitrates, calcium-channel blockers, antiarrhythmic drugs, and magnesium.  They conclude that beta-adrenergic antagonists are effective in reducing mortality during and after AMI (relative risk 0.87 and 0.77) and that ACE inhibitors are effective in reducing mortality after AMI in patients with left ventricular dysfunction (relative risk 0.78).